(From left: Ph Lim En Ni (Chief Pharmacist and Engagement Director of Alpro Group); Dr. Kam San Dhit (Family Doctor & Clinic Manager of Alpro Clinic); Mr Cheong Yee Kok (General Manager & Head of Human Pharma of Boehringer Ingelheim Malaysia, Singapore & Indonesia); Ms Angie H'ng Ai Ai (Head of Therapeutic Area Franchise in Customer Relationship Management of Boehringer Ingelheim Malaysia, Singapore & Indonesia); Dr Jamal Malik (Head of Medicine of Boehringer Ingelheim Malaysia)
Hashtag: #AlproGroup
The issuer is solely responsible for the content of this announcement.
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
MLR: MPR-MY-100236
** The press release content is from Media OutReach Newswire. Bastille Post is not involved in its creation. **
